Brivaracetam Glenmark: Uses, Dosage & Side Effects

What Is Brivaracetam Glenmark and What Is It Used For?

Brivaracetam Glenmark contains the active substance brivaracetam, a next-generation antiepileptic drug (AED) that belongs to the chemical class of pyrrolidone derivatives. It is a generic formulation manufactured by Glenmark Pharmaceuticals, containing the same active ingredient and demonstrating bioequivalence to the originator product. Brivaracetam was developed as a structural analog of levetiracetam, with the specific goal of achieving greater potency and selectivity for its molecular target, synaptic vesicle protein 2A (SV2A). SV2A is an integral membrane glycoprotein found ubiquitously on the surface of synaptic vesicles throughout the central nervous system, where it plays a fundamental role in regulating the calcium-dependent exocytosis of neurotransmitters from presynaptic terminals.

The molecular mechanism through which brivaracetam exerts its antiseizure effects centers on its high-affinity interaction with SV2A. In preclinical studies, brivaracetam demonstrated approximately 15 to 30 times higher binding affinity for SV2A compared to levetiracetam, its predecessor in the same pharmacological lineage. This enhanced affinity translates into more potent modulation of synaptic vesicle function at lower drug concentrations. When brivaracetam binds to SV2A, it is thought to alter the conformational dynamics of the protein in a way that reduces the probability of neurotransmitter release during pathological high-frequency neuronal firing—the type of aberrant electrical activity that underlies epileptic seizures—while having comparatively less impact on normal physiological neurotransmission. This selectivity for pathological over physiological signaling is a key feature that contributes to the drug’s tolerability profile.

Brivaracetam Glenmark is indicated as adjunctive therapy (add-on treatment) for the management of focal (partial-onset) seizures with or without secondary generalization in patients aged 2 years and older who have been diagnosed with epilepsy. Focal seizures, also known as partial-onset seizures according to the International League Against Epilepsy (ILAE) classification, originate from a localized network of neurons within one cerebral hemisphere. These seizures may remain focal (affecting awareness or not) or may evolve to bilateral tonic-clonic activity (formerly called secondary generalization). Focal epilepsy is the most common form of epilepsy, accounting for approximately 60% of all epilepsy cases worldwide, affecting an estimated 30 million people globally.

The clinical efficacy of brivaracetam has been established through a robust program of phase II and phase III randomized, double-blind, placebo-controlled clinical trials involving thousands of patients with drug-resistant focal epilepsy. Three pivotal phase III trials (N01252, N01253, and N01358) enrolled a total of over 1,550 adult patients with focal seizures who were inadequately controlled despite treatment with one or two concomitant antiepileptic drugs. In these trials, brivaracetam at doses of 50 mg/day, 100 mg/day, and 200 mg/day demonstrated statistically significant and clinically meaningful reductions in focal seizure frequency compared to placebo over 12-week treatment periods.

In the pivotal N01358 trial, patients receiving brivaracetam 100 mg/day experienced a median percent reduction in focal seizure frequency of 24.4% over baseline compared to 0.4% for placebo (p=0.0360), while those receiving 200 mg/day showed a reduction of 24.0% (p=0.0274). The 50% responder rate—the proportion of patients achieving at least a 50% reduction in seizure frequency—was significantly higher in the brivaracetam groups across all doses. Long-term open-label extension studies have demonstrated sustained efficacy over periods of up to 8 years, with approximately 30–40% of patients maintaining a 50% or greater reduction in seizure frequency during prolonged treatment.

Brivaracetam was first approved by the European Medicines Agency (EMA) in January 2016 and by the U.S. Food and Drug Administration (FDA) in February 2016, under the brand name Briviact. Since then, it has been approved in more than 70 countries worldwide. The approval of generic formulations, including Brivaracetam Glenmark, reflects the established safety and efficacy profile of the molecule and increases access to this important antiepileptic therapy by providing a more cost-effective treatment option for patients and healthcare systems. Generic brivaracetam formulations must meet the same rigorous quality, purity, and bioequivalence standards as the originator product to receive regulatory approval.

What Should You Know Before Taking Brivaracetam Glenmark?

Contraindications

Brivaracetam Glenmark must not be used if you are allergic (hypersensitive) to brivaracetam, to any other pyrrolidone derivatives (such as levetiracetam or piracetam), or to any of the other ingredients in the tablet. An allergic reaction may manifest as skin rash, itching, swelling of the face, lips, tongue, or throat, or difficulty breathing. If you have experienced a severe allergic reaction to levetiracetam in the past, discuss this with your doctor before starting brivaracetam, as cross-reactivity between pyrrolidone derivatives is possible though not inevitable.

There are no absolute contraindications based on organ function, though the dose may need to be adjusted in patients with hepatic impairment. Patients with severe hepatic insufficiency (Child-Pugh Class C) should use brivaracetam with caution and at reduced doses, as the drug is primarily metabolized in the liver. Brivaracetam has not been specifically studied in patients with end-stage renal disease requiring dialysis, though given its primarily hepatic metabolism, renal impairment alone does not generally necessitate dose adjustment.

Warnings and Precautions

Antiepileptic drugs, including brivaracetam, have been associated with an increased risk of suicidal ideation and behavior. A meta-analysis conducted by the FDA, encompassing data from 199 placebo-controlled clinical trials of 11 different antiepileptic drugs, found that patients receiving AEDs had approximately twice the risk of suicidal thoughts or behavior (0.43%) compared to those receiving placebo (0.24%). This increased risk was observed as early as one week after starting treatment and persisted throughout the duration of treatment evaluated. Patients, caregivers, and family members should be advised to monitor for the emergence or worsening of depression, unusual changes in mood or behavior, and any suicidal thoughts. Any concerning symptoms should be reported to a healthcare provider immediately.

Brivaracetam can cause central nervous system (CNS) depression, manifesting as somnolence (drowsiness), fatigue, dizziness, and impaired coordination. These effects are generally dose-related and are most pronounced during the initial weeks of treatment or following dose increases. Patients should be cautioned about operating motor vehicles, machinery, or engaging in other activities requiring mental alertness until they have gained sufficient experience with brivaracetam to determine whether it adversely affects their ability to perform these tasks. The combination of brivaracetam with other CNS depressants, including alcohol, benzodiazepines, opioids, and sedating antihistamines, may potentiate these sedative effects.

Abrupt discontinuation of brivaracetam, like other antiepileptic drugs, should be avoided as it may precipitate increased seizure frequency, status epilepticus, or withdrawal seizures. When treatment with brivaracetam needs to be discontinued, it is recommended to taper the dose gradually over a period of at least one week. The exact tapering schedule should be determined by the prescribing physician based on individual patient factors, including the current dose, duration of treatment, seizure type, and concomitant medications.

Pregnancy and Breastfeeding

Brivaracetam should preferably not be used during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus. Animal reproductive studies have shown adverse developmental effects (increased embryofetal mortality and reduced fetal body weights) at doses associated with maternal toxicity, though no teratogenic effects (structural malformations) were observed at clinically relevant exposures. However, there are limited human data on the use of brivaracetam during pregnancy. Women of childbearing potential should use effective contraception during treatment and should discuss family planning with their epilepsy specialist before conception.

It is important to note that uncontrolled seizures during pregnancy pose significant risks to both mother and fetus, including physical injury, hypoxia, and in severe cases, maternal or fetal death. Therefore, the decision to continue or modify antiepileptic therapy during pregnancy must be made on an individual basis, weighing the risks of medication exposure against the risks of uncontrolled seizures. Women taking brivaracetam who become pregnant or plan to become pregnant should contact their physician immediately but should not stop the medication without medical guidance.

Brivaracetam is excreted in human breast milk. The concentration of brivaracetam in breast milk has not been fully characterized, but based on animal data, it is expected to be present. A decision must be made whether to discontinue breastfeeding or to discontinue brivaracetam therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother. If breastfeeding is continued during brivaracetam treatment, the infant should be monitored for potential adverse effects including excessive sedation, poor feeding, and developmental milestones.

How Does Brivaracetam Glenmark Interact with Other Drugs?

Brivaracetam is primarily metabolized through three pathways: hydrolysis of the acetamide moiety (the principal route, independent of cytochrome P450 enzymes), hydroxylation via CYP2C19, and to a lesser extent, CYP2C9 and CYP3A4. Unlike many antiepileptic drugs, brivaracetam has a relatively clean interaction profile because its primary metabolic pathway is non-CYP-mediated. Nevertheless, several clinically relevant interactions have been identified and should be considered when prescribing brivaracetam as part of a multidrug antiepileptic regimen.

Major Interactions

Carbamazepine: Co-administration of brivaracetam with carbamazepine results in a modest but clinically relevant reduction in brivaracetam plasma concentrations (approximately 26% decrease in AUC). Carbamazepine is a potent inducer of multiple CYP enzymes and drug transporters, which accelerates the metabolism of brivaracetam. While the clinical impact of this interaction is modest, physicians should be aware that patients taking carbamazepine concurrently may require higher doses of brivaracetam to achieve optimal seizure control. No dose adjustment of carbamazepine is needed when brivaracetam is added.

Phenytoin: Brivaracetam has been shown to increase plasma concentrations of phenytoin by approximately 20%, likely through inhibition of CYP2C19-mediated metabolism of phenytoin. Since phenytoin has a narrow therapeutic index and nonlinear pharmacokinetics, even modest increases in its plasma levels can lead to clinically significant toxicity (nystagmus, ataxia, somnolence). Phenytoin levels should be monitored when brivaracetam is initiated or discontinued, and the phenytoin dose should be adjusted accordingly.

Rifampicin and other strong enzyme inducers: Rifampicin, a potent inducer of multiple drug-metabolizing enzymes and transporters, can reduce brivaracetam plasma levels by approximately 45%. This reduction may significantly compromise seizure control. If co-administration is unavoidable, the prescribing physician should consider increasing the brivaracetam dose and closely monitoring seizure frequency. St. John’s wort (Hypericum perforatum) is a herbal preparation that similarly induces drug-metabolizing enzymes and may reduce brivaracetam levels; concurrent use should be avoided.

Minor Interactions

Oral contraceptives: Brivaracetam does not affect the pharmacokinetics of ethinylestradiol or levonorgestrel at therapeutic doses. Therefore, no dose adjustment of hormonal contraceptives is required when used with brivaracetam, and contraceptive efficacy is not expected to be compromised. This is an important advantage for women of childbearing age, as several other antiepileptic drugs (notably carbamazepine, phenytoin, phenobarbital, and topiramate at high doses) significantly reduce the effectiveness of hormonal contraception.

Levetiracetam: Since both brivaracetam and levetiracetam target SV2A, there is a pharmacodynamic interaction when used together. Clinical trials showed no additional efficacy benefit from combining the two drugs, while the side effect burden may increase. Concurrent use of brivaracetam and levetiracetam is generally not recommended; when switching from levetiracetam to brivaracetam, the transition should be managed by an epilepsy specialist.

What Is the Correct Dosage of Brivaracetam Glenmark?

Adults

For adults (18 years and older) and adolescents weighing 50 kg or more, the recommended starting dose of Brivaracetam Glenmark is 25 mg taken orally twice daily, giving a total daily dose of 50 mg. Based on individual clinical response and tolerability, the dose may be increased in increments to 50 mg twice daily (100 mg/day), 75 mg twice daily (150 mg/day), or up to a maximum of 100 mg twice daily (200 mg/day). Each dose adjustment should be considered after an adequate observation period, typically 1–2 weeks, to allow steady-state concentrations to be achieved and clinical effects to be evaluated.

In clinical practice, many epilepsy specialists will start patients at 50 mg/day and titrate upward over 2–4 weeks to the target maintenance dose, which is most commonly 100–200 mg/day. However, unlike many other antiepileptic drugs, brivaracetam can also be initiated at the target therapeutic dose without a prolonged titration period due to its rapid absorption, near-complete bioavailability, and relatively favorable tolerability profile at standard doses. This rapid initiation approach may be particularly useful in clinical situations requiring urgent seizure control.

Children

Brivaracetam is approved for use in children from 2 years of age. In pediatric patients, dosing is weight-based to ensure appropriate drug exposure relative to body size. For children and adolescents weighing 50 kg or more, the same dosing regimen as adults applies (starting dose 25 mg twice daily, up to a maximum of 100 mg twice daily). For children weighing between 20 kg and less than 50 kg, the recommended starting dose is 0.5–1 mg/kg twice daily, with a therapeutic range of 0.5–2 mg/kg twice daily. For children weighing between 10 kg and less than 20 kg, the starting dose is similarly 0.5–1 mg/kg twice daily, with the option to increase to up to 2.5 mg/kg twice daily.

It is important to note that the 10 mg film-coated tablet formulation of Brivaracetam Glenmark may not be suitable for precise weight-based dosing in younger or smaller children. For patients who require doses that cannot be accurately achieved with available tablet strengths, an oral solution formulation (10 mg/mL) may be more appropriate and is available from other manufacturers. Parents and caregivers should use the dosing formulation recommended by the child’s treating physician to ensure accurate dosing.

Elderly

No dose adjustment is specifically required in elderly patients (65 years and older) based solely on age. However, clinical experience with brivaracetam in patients older than 65 is limited compared to younger adults. Elderly patients are generally more susceptible to CNS-depressant effects and may have reduced hepatic and renal function, which could affect drug metabolism and clearance. A conservative approach to dosing in this population is advisable, starting at the lower end of the therapeutic range and titrating more slowly. Elderly patients are also more likely to be taking multiple concomitant medications, increasing the potential for pharmacodynamic interactions (particularly additive sedation with other CNS-active drugs) and the importance of medication review.

Missed Dose

If you miss a dose of Brivaracetam Glenmark, take it as soon as you remember. However, if it is nearly time for your next scheduled dose (within approximately 6 hours), skip the missed dose and take the next dose at the regular time. Do not take a double dose to make up for a missed one, as this may increase the risk of side effects, particularly CNS-related effects such as drowsiness, dizziness, and impaired coordination. Maintaining a consistent dosing schedule (approximately every 12 hours) is important for maintaining stable drug levels and optimal seizure control.

Overdose

There is limited clinical experience with brivaracetam overdose. In clinical studies, doses up to 1,400 mg (7 times the maximum recommended daily dose) were administered without life-threatening toxicity. Symptoms of overdose are expected to be extensions of the drug’s known pharmacological effects and may include pronounced dizziness, somnolence, nausea, vomiting, and impaired balance and coordination. There is no specific antidote for brivaracetam. In the event of a suspected overdose, standard supportive measures should be applied, including monitoring of vital signs and observation of clinical status. Hemodialysis is not expected to be an effective method of removing brivaracetam from the body, as the drug is approximately 20% protein-bound and its primary metabolites are pharmacologically inactive.

What Are the Side Effects of Brivaracetam Glenmark?

Like all medicines, Brivaracetam Glenmark can cause side effects, although not everybody experiences them. The safety profile of brivaracetam has been extensively characterized through clinical trials involving more than 3,000 patients with epilepsy, as well as post-marketing surveillance data accumulated since its approval in 2016. The most commonly reported adverse reactions are related to the drug’s effects on the central nervous system, reflecting its mechanism of action in modulating neuronal activity. These CNS effects are generally dose-dependent, meaning they occur more frequently and with greater intensity at higher doses, and they tend to diminish over the first few weeks of treatment as the body adapts to the medication.

In pooled analyses of the pivotal phase III clinical trials, the overall incidence of adverse events was approximately 60–65% in patients receiving brivaracetam compared to approximately 50–55% in those receiving placebo. The rate of treatment discontinuation due to adverse events was approximately 6–8% for brivaracetam compared to 4% for placebo, indicating that the majority of side effects are manageable and do not necessitate stopping treatment. The following frequency classification is based on convention used in clinical pharmacology: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (<1/1,000).

One notable aspect of brivaracetam’s safety profile, which distinguishes it from its predecessor levetiracetam, is the relatively lower incidence of behavioral and psychiatric adverse effects. While levetiracetam is well-known for causing irritability, aggression, and mood disturbances in a significant proportion of patients (up to 13–15% in some series), brivaracetam appears to have a more favorable behavioral profile. In a post-hoc analysis of pooled clinical trial data comparing patients who switched directly from levetiracetam to brivaracetam, those who had experienced behavioral side effects on levetiracetam showed improvement in these symptoms after switching to brivaracetam, with up to 50% of patients reporting resolution of behavioral problems.

Nonetheless, psychiatric adverse effects remain a concern with all antiepileptic drugs, and brivaracetam is no exception. Patients with a pre-existing history of psychiatric disorders, including depression, anxiety, and psychosis, may be at higher risk and should be monitored closely during treatment. If new or worsening psychiatric symptoms develop, the treating physician should reassess the benefit-risk balance of continued brivaracetam therapy.

How Should You Store Brivaracetam Glenmark?

Brivaracetam Glenmark film-coated tablets should be stored at room temperature, not exceeding 25°C (77°F). The tablets should be kept in their original packaging (blister pack or bottle, as applicable) until ready for use, as this protects the medication from moisture and light exposure, both of which can degrade the active ingredient and reduce the medication’s effectiveness over time. Do not store brivaracetam in the bathroom, near a kitchen sink, or in other areas with high humidity or temperature fluctuations.

Keep this medication out of the sight and reach of children. Accidental ingestion of antiepileptic medication by young children can cause serious neurological symptoms including excessive drowsiness, impaired coordination, and in severe cases, respiratory depression. If a child accidentally ingests brivaracetam, seek emergency medical attention immediately.

Do not use Brivaracetam Glenmark after the expiry date (EXP) printed on the carton, blister, or bottle label. The expiry date refers to the last day of that month. If the tablets show any visible signs of deterioration (unusual discoloration, crumbling, or unusual odor), do not take them and consult your pharmacist. Do not dispose of medicines via household waste or wastewater. Ask your pharmacist about proper disposal methods for medicines you no longer use, as this helps protect the environment from pharmaceutical contamination.

What Does Brivaracetam Glenmark Contain?

The active substance in Brivaracetam Glenmark is brivaracetam. Each film-coated tablet contains 10 mg of brivaracetam. Brivaracetam (chemical name: (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide) is a white to off-white crystalline powder with a molecular weight of 212.29 g/mol and the molecular formula C₁₁H₂₀N₂O₂. It is freely soluble in water and common organic solvents, which contributes to its near-complete oral bioavailability.

In addition to the active ingredient, the tablets contain inactive excipients (non-active ingredients) that serve essential pharmaceutical functions. The tablet core typically contains excipients such as:

• Croscarmellose sodium – a disintegrant that helps the tablet break apart in the gastrointestinal tract, promoting rapid and complete dissolution of the active ingredient
• Lactose monohydrate – a filler/diluent used to give the tablet its appropriate size and weight. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should consult their doctor before taking this medicine
• Microcrystalline cellulose – a filler and binder that provides structural integrity to the tablet
• Magnesium stearate – a lubricant that prevents the tablet mixture from sticking to manufacturing equipment during compression

The film-coating of the tablet typically contains:

• Polyvinyl alcohol – a film-forming polymer that provides a smooth coating
• Titanium dioxide (E171) – a white colorant that gives the tablet its appearance and protects the active ingredient from light
• Macrogol (polyethylene glycol) – a plasticizer that makes the film-coating flexible
• Talc – an anti-caking agent used in the coating
• Iron oxide yellow (E172) – a colorant for tablet identification (may vary by strength)

The exact excipient composition may vary slightly between generic manufacturers while maintaining pharmaceutical equivalence. Always check the patient information leaflet included with your specific product for the complete list of ingredients. If you have known allergies or intolerances to any pharmaceutical excipients, particularly lactose, discuss this with your pharmacist or prescribing physician before starting treatment.